VIRPAX PHARMS INC by Virpax Pharmaceuticals, Inc. Analyst Price Targets - Benzinga

VIRPAX PHARMS INC by Virpax Pharmaceuticals, Inc.

VRPXOTCEM

Trade with Public

Trade with Public

$0.00010

-0.67-99.99%

At close: Apr 15, 5:00 PM EST

Overview News Earnings ForecastPrice TargetsFinancials Sentiment Ownership Compare

VIRPAX PHARMS INC by Virpax Pharmaceuticals, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for VIRPAX PHARMS INC by Virpax Pharmaceuticals, Inc. (VRPX).

Price Target Range —

Analyst Consensus — 1 Analysts

1Hold

# Analysts1

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2024	Maxim Group	Naz Rahman	Downgrade	Buy→Hold	—
Jul 19, 2024	Maxim Group	Naz Rahman	Upgrade	Hold→Buy	$3
May 22, 2024	Maxim Group	Naz Rahman	Downgrade	Buy→Hold	—

More with Benzinga EdgeGet Access

Analyst Ratings News

US Stocks Likely To Open Higher Following A Sell-Off, 'This Choppy Start To 2025 Isn't Abnormal. Don't Panic,' Says Expert Highlighting Seasonal Weakness In The First Quarter After Elections

U.S. stock futures rose on Friday following Thursday's sell-off. Futures advanced except the small-cap gauge Russell 2000.

Rishabh Mishra

This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday

Avi Kapoor

PRO
Maxim Group Downgrades Virpax Pharmaceuticals to Hold

Maxim Group analyst Naz Rahman downgrades Virpax Pharmaceuticals (NASDAQ:VRPX) from Buy to Hold.

Benzinga Newsdesk

PRO
Maxim Group Upgrades Virpax Pharmaceuticals to Buy, Announces $3 Price Target

Maxim Group analyst Naz Rahman upgrades Virpax Pharmaceuticals (NASDAQ:VRPX) from Hold to Buy and announces $3 price target.

Benzinga Newsdesk

PRO
Maxim Group Downgrades Virpax Pharmaceuticals to Hold

Maxim Group analyst Naz Rahman downgrades Virpax Pharmaceuticals (NASDAQ:VRPX) from Buy to Hold.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2022

Benzinga Insights